Developmental and Epileptic Encephalopathies Market Poised for 11.7% CAGR Growth Through 2036, Driven by Next-Generation Gene and Targeted Therapies
核心洞察
The developmental and epileptic encephalopathies (搜索) (DEE) market reached USD 2.2 billion across the 7MM in 2025, with the United States accounting for approximately 59% of the total market share.
The diagnosed prevalent population of DEE in the 7MM is projected to rise from approximately 288,000 in 2025 to 326,000 by 2036, reflecting improved genetic testing and diagnostic awareness.
A robust pipeline featuring antisense oligonucleotides, gene therapies, and precision medicines—including zorevunersen, bexicaserin, and relutrigine—is expected to reshape the treatment landscape for genetically defined DEE subtypes.
The global developmental and epileptic encephalopathies (搜索) (DEE) market is on track for transformative growth, with DelveInsight's newly published market analysis projecting an 11.7% compound annual growth rate (CAGR) from 2026 to 2036. The market, valued at USD 2.2 billion across the seven major markets (7MM: United States, EU4, United Kingdom, and Japan) in 2025, is being propelled by an expanding pipeline of next-generation gene and targeted therapies aimed at the root genetic causes of these severe pediatric neurological disorders.
The United States dominates the current treatment landscape, capturing approximately 59% of the total DEE market in the 7MM in 2025. The diagnosed prevalent population of DEE across these markets is expected to climb from roughly 288,000 cases in 2025 to approximately 326,000 by 2036, with the U.S. alone accounting for about 50% of the 7MM diagnosed prevalent population.
Pipeline Innovation Targets Genetic Roots of Disease
The DEE therapeutic pipeline is undergoing a fundamental shift from symptomatic seizure control toward disease-modifying strategies that address underlying molecular and genetic drivers. Antisense oligonucleotides (ASOs), gene therapies, and RNA-based treatments are being actively explored across conditions including Dravet syndrome (搜索), Angelman syndrome (搜索), SCN2A (搜索)-DEE, and CDKL5 deficiency disorder (搜索) (CDD).
Aparna Thakur, Assistant Project Manager, Forecasting at DelveInsight, noted that "antisense therapies are emerging as a targeted approach for DEE, designed to modulate gene expression at the RNA level and address the underlying genetic causes of disease. Candidates such as elsunersen and zorevunersen exemplify this strategy, aiming to correct aberrant splicing or regulate pathogenic gene activity associated with specific DEE subtypes."
By 2036, Stoke Therapeutics' zorevunersen (STK-001) is anticipated to lead the emerging DEE market in the 7MM, followed by Longboard Pharmaceuticals' bexicaserin (LP352) and Praxis Precision Medicines' relutrigine (PRAX-562).
Zorevunersen: First Disease-Modifying Approach for Dravet Syndrome (搜索)
Stoke Therapeutics' zorevunersen is a proprietary antisense oligonucleotide designed to increase NaV1.1 (搜索) protein expression by utilizing the healthy copy of the SCN1A (搜索) gene. This RNA-based approach aims to restore normal physiological NaV1.1 levels, potentially reducing both seizure frequency and associated non-seizure comorbidities without altering or inserting DNA. The candidate has secured orphan drug designation from both the FDA and EMA, along with rare pediatric disease designation from the FDA, and is currently in Phase III clinical trials for Dravet syndrome (搜索).
Bexicaserin: A Novel 5-HT2C (搜索) Superagonist
Longboard Pharmaceuticals, now acquired by Lundbeck, is advancing bexicaserin—an orally administered, centrally acting 5-HT2C (搜索) superagonist—for seizures associated with multiple DEEs, including Dravet syndrome (搜索), Lennox–Gastaut syndrome (搜索) (LGS), tuberous sclerosis complex (搜索) (TSC), and CDD. The therapy regulates GABA signaling to reduce neuronal hyperexcitability and is currently the only 5-HT2C receptor superagonist being dose-optimized specifically for refractory epilepsy. Bexicaserin is undergoing Phase III clinical evaluation, and in December 2025, Lundbeck presented positive Phase II long-term data at the American Epilepsy Society Annual Meeting.
Apazunersen (搜索) and Rugonersen Target Angelman Syndrome (搜索)
Ultragenyx Pharmaceutical's apazunersen (搜索) (GTX-102) is an investigational ASO-based therapy that inhibits the UBE3A (搜索)-antisense transcript, enabling reactivation of the normally silenced paternal UBE3A gene in neurons. The therapy has received Breakthrough Therapy Designation, Orphan Drug Designation, and Fast Track Designation from the FDA, as well as PRIME designation from the EMA, and is currently in Phase III clinical development.
Oak Hill Bio (搜索) and Roche's rugonersen (RO7248824) similarly targets the UBE3A (搜索)-antisense transcript to increase paternal UBE3A gene expression. Following encouraging findings from the Phase I TANGELO study, Oak Hill Bio plans to commence a pivotal Phase III clinical trial in the second quarter of 2026, positioning rugonersen as a potential best-in-class therapy for Angelman syndrome (搜索).
Regulatory Momentum Builds
The regulatory landscape for DEE therapies has seen significant activity. In March 2026, Praxis Precision Medicines announced that the FDA accepted for Priority Review its New Drug Application for relutrigine for the treatment of SCN2A (搜索) and SCN8A DEEs, with a PDUFA target action date of September 27, 2026. In January 2026, Encoded Therapeutics (搜索) received FDA Breakthrough Therapy Designation for ETX101 in Dravet syndrome (搜索), and in March 2026, the company completed a Regenerative Medicine Advanced Therapy meeting with the FDA, achieving alignment on the pivotal study design to support a planned Biologics License Application.
Current Treatment Landscape and Unmet Need
Over the past decade, the DEE therapeutic space has advanced with syndrome-specific approvals including cannabidiol (EPIDIOLEX), fenfluramine (FINTEPLA), ganaxolone (ZTALMY), and everolimus (AFINITOR/VOTUBIA) for conditions such as Dravet syndrome (搜索), LGS, CDD, and TSC. Ganaxolone holds a strong competitive position as the only FDA-approved therapy specifically indicated for CDD, supported by significant market exclusivity.
However, these approved therapies carry notable safety burdens. Fenfluramine has a boxed warning for valvular heart disease and pulmonary arterial hypertension requiring REMS-guided cardiac monitoring, while cannabidiol has been associated with elevated liver enzymes necessitating regular hepatic assessments. Despite recent progress, many genetically defined DEE subtypes still lack approved targeted treatment options, leaving considerable unmet clinical need.
The broader pipeline includes additional candidates such as elsunersen (PRAX-222) from Praxis Precision Medicines, EPX-100 (clemizole hydrochloride) from Harmony Biosciences, carisbamate (YKP509) from SK Life Science, obudanersen (ION582) from Ionis Pharmaceuticals, ETX101 from Encoded Therapeutics (搜索), tricaprilin (CER-0001) from Cerecin Neurosciences, and BMB-101 from Bright Minds Biosciences, among others. As these cutting-edge therapies mature and gain regulatory approval, they are expected to reshape the DEE treatment paradigm, offering new standards of care for patients with these devastating pediatric epileptic disorders.